Shares of Gain Therapeutics, Inc. (GANX) have been struggling lately and have lost 6.5% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the f ...

股票走势分析 - Gain Therapeutics, Inc. (GANX) 最近出现了明显的下降趋势，股票在过去四周下跌了25.9% [1] - RSI是一种常用的技术指标，用于判断股票是否被卖空 [2] - RSI在0到100之间波动，当股票的RSI低于30时通常被认为是被卖空的 [3] - RSI有助于快速检查股票价格是否即将反转 [4] - GANX股票的RSI读数为29.43，表明卖空压力可能即将消耗殆尽，股票的趋势可能很快会逆转 [5] 盈利预期分析 - 分析师对GANX的盈利预期普遍看好，这导致了过去30天内共识EPS预期增长了0.9% [6] - GANX目前具有Zacks Rank 2（买入），这意味着它在我们根据盈利预期修订和EPS惊喜趋势对超过4,000只股票进行排名时处于前20% [7]

BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024. "We are thrilled to welcome Gene as our new CFO," commented Gain CEO Matthias Alder. "His experience as an operational CFO with a track record ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40237 GAIN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 85-1726310 (State or Other Jurisdiction of I ...

Exhibit 99.1 Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update BETHESDA, Md., March 26, 2024 – Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the year ended December 31, 2023 and provides a corporate update. Corporate Highlights from Q4 2023 to Date ● Presented data at AD/P ...

BETHESDA, Md., March 15, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 at Old Parkland in Dallas, TX. Public Ventures Discovery DayDate: Tuesday, March 19, 2024Presentation: 2:30 PM CSTLocation: Pecan Room, Old Parkland, 3819 Maple A ...

BETHESDA, Md., March 15, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced participation in the upcoming Public Ventures Discovery Day on March 19, 2024 at Old Parkland in Dallas, TX. Public Ventures Discovery DayDate: Tuesday, March 19, 2024Presentation: 2:30 PM CSTLocation: Pecan Room, Old Parkland, 3819 Maple ...

Gain Therapeutics, Inc.新药GT-02287作用机制 - GT-02287与内质网中的葡萄糖苷酶(GCase)相互作用，帮助正确折叠GCase[1] - 防止GCase酶突变的内质网滞留、内质网应激和相关降解[2] - 增强溶酶体活性和高效处理GCase底物葡糖鞘氨醇[3]

Gain Therapeutics宣布启动GT-02287的Phase 1临床试验的Multiple Ascending Dose (MAD)部分 - GT-02287已被证明可以恢复溶酶体酶葡萄糖酸酶(GCase)的功能，有望减缓帕金森病的进展[3] - GT-02287是一种口服、穿透血脑屏障的小分子药物，可以恢复蛋白酶酶的功能，改善运动功能[4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40237 GAIN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 85-1726310 (State or other ju ...